Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Bioequivalence Study of Tipranavir Stored at Controlled Temperature Compared With Tipranavir Stored at Controlled Refrigerated Conditions, Orally Co-administered With Ritonavir in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TPV - Refrigerated conditions
Drug: TPV - Room condition
Drug: Ritonavir (RTV)

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02253888

Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBT 986 BS - high
Drug: BIBT 986 BS - low
Drug: Placebo

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02254083

Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBT 986 BS - single rising dose
Drug: Placebo

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 47

Registration Number: NCT02254057

Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus

Phase 1

Terminated

Conditions: Carcinoma, Squamous Cell

Interventions: Drug: bivatuzumab mertansine

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7

Registration Number: NCT02254044

Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tadalafil
Drug: Tipranavir
Drug: Ritonavir

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 17

Registration Number: NCT02253862

Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Serevent® Diskus®
Drug: Spiriva®
Drug: Tiotropium/Salmeterol

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02254174

Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male/Female Volunteers

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Matching placebo
Drug: BI 1181181 Healthy young
Drug: BI 1181181 healthy elderly

First Posted Date: 2014-10-01

Last Posted Date: 2018-08-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02254161

Locations: 🇩🇪
1344.2.1 Boehringer Ingelheim Investigational Site, Berlin, Germany

Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBT 986 BS

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 23

Registration Number: NCT02254070

Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Dipyridamole
Drug: Aggrenox
Drug: Lansoprazole
Drug: Aspirin

First Posted Date: 2014-09-29

Last Posted Date: 2014-09-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 31

Registration Number: NCT02251184

Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir
Drug: Ritonavir
Drug: Darunavir
Drug: Aspirin

First Posted Date: 2014-09-29

Last Posted Date: 2014-09-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 52

Registration Number: NCT02251795

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy